Actavis’ generics R&D team is highly regarded as one of the best in the industry, driving a world-class generics pipeline which continues to hold an industry-leading position in First-to-File opportunities in the U.S. and more than 1,000 marketing authorizations globally.
Our Generics R&D strategy is focused on development activities that support sustainable long-term organic growth:
- Off-patent drugs that are difficult to develop or manufacture, or that complement or broaden our existing product lines;
- Patent challenge products where the company believes either the brand patent is invalid or its product does not infringe; and
- The development of sustained-release, semi-solid, liquid, oral transmucosal, transdermal, gel, injectable, inhalation and other drug delivery technologies and the application of these technologies to proprietary drug forms.